Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in ...

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal with Roche, go here; and to read about the panels at our Breakthrough East ...

Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and while H.C. Wainwright analyst Douglas Tsao was ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...

BofA lowered the firm’s price target on Immunovant (IMVT) to $33 from $38 and keeps a Buy rating on the shares after yesterday’s topline data ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.

Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

Immunovant's experimental drug to treat a type of chronic muscle weakness improved patients' ability to perform daily tasks, but fell short of the effectiveness set by already approved treatments. The ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...